Accession Number:

ADA470148

Title:

Fish Oil Supplementation and Fatty Acid Synthase Expression in the Prostate: A Randomized Controlled Trial

Descriptive Note:

Final rept. 1 Mar 2004-28 Feb 2007

Corporate Author:

OREGON HEALTH AND SCIENCES UNIV PORTLAND

Personal Author(s):

Report Date:

2007-03-01

Pagination or Media Count:

7.0

Abstract:

We are conducting a double-blind, placebo-controlled, randomized intervention study to evaluate the effects of Fish Oil FO supplementation use on markers of lipid metabolism in prostate tissue samples. The primary endpoints of this trial are fatty acid synthase expression, caveolin-1 expression, changes in lipid raft fractions in the plasma membrane and cell proliferation KI-87 expression in benign, pre-neoplastic and neoplastic prostate tissue. The secondary endpoints include measuring the expression of SREBP-1, a transcription factor for fatty acid concentration and change in PSA. Subjects are men from the Portland VA Medical Center PVAMC, the Oregon Health and Science University OHSU and Kaiser Permanente Northwest KPNWurology clinics who are scheduled for a repeat biopsy. These men will have had an initial negative biopsy yet are still considered at high risk due to continued elevated prostatic specific antigen PSA4microgramsdf, are positive for PIN, have suspicious findings by DRE or TRUS, or other clinical finding. Approximately 5 men per month over 24 months will be recruited and randomized to receive three months of either fish oil capsules treatment 1 or olive oil placebo capsules treatment 2. Potential confounding cariables are assessed through completion of a comprehensive diet history questionnaire and risk factor questionnaire, assessment of pre and post-treatment PSA and surveillance of medication and supplement use. Compliance will be assessed using pill count and evaluation of RBC fatty acid concentrations. While this study population is limited to men at high risk of disease, the results may be more broadly generalizable to any man considered at risk of prostate cancer due to standard clinical indicators such as a PSA4microgramsml.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE